Beom Hee Choi

Beom Hee Choi

Auto-generated profile, based on publicly available information

Beom Hee Choi

GC I-Med Seoul Forest, Seoul, Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2025 in Cancer Research
Verified
Journal Article
Closed access
TLTae-Rim Lee
Tae-Rim Lee
JAJin Mo Ahn
Jin Mo Ahn
JLJunnam Lee
Junnam Lee
DKDasom Kim
Dasom Kim
JPJuntae Park
Juntae Park
ECEun-Hae Cho
Eun-Hae Cho
Early detection of lung cancer is important for improving patient survival rates. Liquid biopsy using whole-genome sequencing of cell-free DNA (cfDNA) offers a promising avenue for lung cancer screening, providing a potential alternative or complementary approach to current screening modalities. Here, we aimed to develop and validate an approach by integrating fragment and genomic features of cfDNA to enhance lung cancer detection accuracy across diverse populations. Deep learning–based classifiers were trained using comprehensive cfDNA fragmentomic features from participants in multi-institutional studies, including a Korean discovery dataset (218 patients with lung cancer and 2,559 controls), a Korean validation dataset (111 patients with lung cancer and 1,136 controls), and an independent Caucasian validation cohort (50 patients with lung cancer and 50 controls). In the discovery dataset, classifiers using fragment end motif by size, a feature that captures both fragment end motif and size profiles, outperformed standalone fragment end motif and fragment size classifiers, achieving an area under the curve (AUC) of 0.917. The ensemble classifier integrating fragment end motif by size and genomic coverage achieved an improved performance, with an AUC of 0.937. This performance extended to the Korean validation dataset and demonstrated ethnic generalizability in the Caucasian validation cohort. Overall, the development of a deep learning–based classifier integrating cfDNA fragmentomic and genomic features in this study highlights the potential for accurate lung cancer detection across diverse populations. Significance: Evaluating fragment-based features and genomic coverage in cell-free DNA offers an accurate lung cancer screening method, promising improvements in early cancer detection and addressing challenges associated with current screening methods.

20 September 2022 in Korean Journal of Family Medicine
Verified
Journal Article
Open access
PDF file
SJSusie Jung
Susie Jung
BCBeom-Hee Choi
Beom-Hee Choi
NJNam-Seok Joo
Nam-Seok Joo
Identifying and preventing modifiable risk factors for cardiovascular disease is very important. Vascular calcification has been studied clinically as an asymptomatic preclinical marker of atherosclerosis and a risk factor for cardio-cerebrovascular disease. It is known that higher homocysteine levels are associated with calcified plaques and the higher the homocysteine level, the higher the prevalence and progression of vascular calcification. Homocysteine is a byproduct of methionine metabolism and is generally maintained at a physiological level. Moreover, it may increase if the patient has a genetic deficiency of metabolic enzymes, nutritional deficiencies of related cofactors (vitamins), chronic diseases, or a poor lifestyle. Homocysteine is an oxidative stress factor that can lead to calcified plaques and trigger vascular inflammation. Hyperhomocysteinemia causes endothelial dysfunction, transdifferentiation of vascular smooth muscle cells, and the induction of apoptosis. As a result of transdifferentiation and cell apoptosis, hydroxyapatite accumulates in the walls of blood vessels. Several studies have reported on the mechanisms of multiple cellular signaling pathways that cause inflammation and calcification in blood vessels. Therefore, in this review, we take a closer look at understanding the clinical consequences of hyperhomocysteinemia and apply clinical approaches to reduce its prevalence.

12 August 2022 in Nutrition Research and Practice
Verified
Journal Article
Open access
PDF file
NKNam-Kyu Kim
Nam-Kyu Kim
MJMin Ah Jung
Min Ah Jung
BCBeom-Hee Choi
Beom-Hee Choi
NJNam-Seok Joo
Nam-Seok Joo
Kim NK, et al. Nutr Res Pract. 2022 Dec;16(6):745-754. https://doi.org/10.4162/nrp.2022.16.6.745

19 November 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
SHSeung Wook Hong
Seung Wook Hong
JPJuntae Park
Juntae Park
JLJunnam Lee
Junnam Lee
JAJin Mo Ahn
Jin Mo Ahn
DKDasom Kim
Dasom Kim
JBJeong-Sik Byeon
Jeong-Sik Byeon
INTRODUCTION: Fragmentomic analysis of blood-derived cell-free DNA (cfDNA) has emerged as a promising approach for cancer screening. We aimed to develop a novel cfDNA-based blood test and evaluate its diagnostic performance for colorectal cancer (CRC) and advanced adenoma (AA). METHODS: In this prospective case-control study, 1,677 participants were enrolled: 1,267 with normal colonoscopy, 302 with CRC, and 108 with AA. Participants were randomly assigned to either a development cohort (n = 1,250) or a validation cohort (n = 427). Whole-genome sequencing of cfDNA was performed to extract fragmentomic features, including end motifs, fragment lengths, and genome-wide coverage. A diagnostic model was developed using the Residual Enrichment From Independent Normal Ensemble method, and its performance was assessed in the validation cohort. RESULTS: In the validation cohort, the sensitivities for CRC and AA were 90.4% (95% CI, 82.2–97.3) and 58.3% (95% CI, 48.1–67.6), respectively. Overall accuracy for advanced neoplasia was 84.8% (95% CI, 81.1–87.8), and specificity in individuals with normal colonoscopy was 94.7% (95% CI, 91.2–96.9). The areas under the receiver operating characteristic curve were 0.978 for CRC and 0.862 for AA. Sensitivities by CRC stage were 84.2% (stage I), 85.0% (stage II), 94.4% (stage III), and 100.0% (stage IV). Diagnostic performance was consistent across CRC locations (left vs right colon), age of patients with CRC (<60 vs ≥60), and AA locations. DISCUSSION: This cfDNA-based blood test demonstrated high diagnostic accuracy for CRC and acceptable performance for AA. Its consistent performance across clinical subgroups suggests its potential as an effective noninvasive CRC screening tool.

31 July 2025 in Cardiovascular Prevention and Pharmacotherapy
Verified
Journal Article
Open access
JCJungkyung Cho
Jungkyung Cho
JSJaewon Seo
Jaewon Seo
JPJunseok Park
Junseok Park
DNDongjin Nam
Dongjin Nam
TPTae Hyun Park
Tae Hyun Park
MJMiso Jang
Miso Jang
Background: Although retinal imaging–based artificial intelligence (AI) tools have recently been introduced for cardiovascular disease (CVD) risk assessment, little is known about the distribution of these AI-derived scores across the full age spectrum or their associations with traditional cardiometabolic risk factors at different ages.Methods: We analyzed data from 138,745 participants who underwent routine health examinations at two health screening centers in Seoul, Korea. The AI-based retinal CVD risk score (Dr.Noon CVD), as well as anthropometric, hemodynamic, and metabolic indices and cardiometabolic disease status, were compared across ages 16 to 96 years. In a subgroup of 13,182 individuals who underwent coronary artery calcium scoring (CACS) by cardiac computed tomography, we evaluated the performance of the Dr.Noon CVD score in detecting CACS using receiver operating characteristic curve analysis.Results: Mean Dr.Noon CVD scores rose steadily with age from 14.2±2.9 (0, and an area under the curve of 0.82 (95% confidence interval, 0.81–0.83) for identifying significant calcification burden, defined as CACS >100.Conclusions: Dr.Noon CVD scores were consistently correlated with age, conventional risk factors, and CACS, suggesting a potential role in broad-based cardiovascular risk stratification and in guiding personalized prevention strategies.

2 May 2025
Verified
Other
Open access
PDF file
TLTae-Rim Lee
Tae-Rim Lee
JAJin Mo Ahn
Jin Mo Ahn
JLJunnam Lee
Junnam Lee
DKDasom Kim
Dasom Kim
JPJuntae Park
Juntae Park
ECEun-Hae Cho
Eun-Hae Cho
Experimental Batch Effect on FEMS Feature Before and After Bias Correction.